Objective To investigate the antiviral effect of tenofovir disoproxil ( TDF) in women with chronic hepatitis B ( CHB) and its effect in blocking mother-to-child transmission of CHB during early pregnancy. Methods A total of 164 pregnant women who were diagnosed with CHB in Nanchang Ninth Hospital from July 2014 to December 2016 were enrolled, and their neonates were also enrolled as subjects. According to their will, the patients were divided into treatment group with 80 patients and control group with 84 patients. The patients in the treatment group were given TDF 300 mg/d during early pregnancy, followed by antiviral therapy for CHB after delivery, and those in the control group did not receive antiviral therapy. All neonates were given hepatitis B immunoglobulin and hepatitis B vaccine after birth.The changes in liver and renal function, electrolytes, myocardial zymogram, routine blood and urine test results, HBV serum markers, and HBV DNA were observed, and adverse reactions were recorded. HBsAg and HBV DNA were measured for infants at birth and at 6 and 12 months after birth; HBV infection, growth and development, and complications were evaluated, and Apgar score was determined. The t-test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between groups. Results There were significant differences between the treatment group and the control group in alanine aminotransferase ( ALT) normalization rate, and HBV DNA clearance rate at 18, 24, and 36 weeks of pregnancy ( ALT normalization rate: χ2= 19. 145, 24. 990, and 36. 414, all P < 0. 001; HBV DNA clearance rate: χ2= 75. 526, 107. 412, and 38. 138, all P < 0. 001) . The infants were evaluated at birth and at 6 and 12 months, and there were significant differences between the treatment group and the control group in HBsAg positive rate ( χ2= 6. 089, 5. 074, and 5. 074, all P < 0. 05) and HBV DNA positive rate ( χ2= 5. 074, P < 0. 05) . There was no significant difference in Apgar score between the two groups ( P > 0. 05) , and their growth and development indices were within normal ranges. Conclusion TDF administration in early pregnancy can help with the recovery of liver function and is safe and effective in blocking the mother-to-child transmission of HBV.
DownLoad: